Alvotech's stock surged 6.13% in pre-market trading on Monday, following a significant regulatory update from the biosimilar developer.
The price movement comes after the company announced that the U.S. Food and Drug Administration has completed a routine cGMP surveillance inspection of its manufacturing facility in Reykjavik, Iceland. The FDA concluded the inspection and issued a Form 483, but Alvotech stated that the observations can be addressed quickly and do not raise any substantial issues with the site or its operations.
This positive inspection outcome positions Alvotech to resubmit its relevant Biologics License Applications (BLAs) in the current quarter. The company continues to expect FDA approval for these biosimilar candidates during 2026, marking a crucial step forward for its product pipeline.
Comments